The European Medicines Agency has validated a Marketing Authorization Application seeking the approval of nirogacestat for patients with desmoid tumors.
29.02.2024 - Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role . Seite 1
– Reported OGSIVEO™ net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application to.
Through serendipity, science, and rigor, SpringWorks Therapeutics, a targeted oncology company, marks success with the first FDA-approved treatment for Desmoid Tumor.
Serendipity and science: Building a multibillion-dollar breakthrough in oncology independantexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from independantexpress.com Daily Mail and Mail on Sunday newspapers.